Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Aute leukemia working group (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT) study

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Authors: Source Type: research

Related Links:

Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls. Patients 18 to 70 years of age with newly diagnosed AML and centrally confirmed FLT3-ITD were eligible: 284 patients were t...
Source: Blood - Category: Hematology Authors: Tags: Myeloid Neoplasia, Clinical Trials and Observations Source Type: research
Condition:   Acute Myeloid Leukemia Interventions:   Drug: Idasanutlin;   Drug: Cytarabine;   Drug: Daunorubicin;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report a retrospective analysis of outcomes of therapy of 24 patients with AML or MDS-EB refractory to high dose salvage chemotherapy or who had failed previous HCT, who received T cell replete HLA haploidentical HCT in aplasia after cladribine/cytarabine based chemotherapy followed by reduced intensity or myeloablative conditioning. All patients had active disease before commencement of the treatment.Results91.7% of patients achieved CR, whereas 2 patients (8.2%) died in aplasia. 1-year relapse rate was 49.3%. Cumulative incidence of non-relapse mortality (NRM) was 25.6%. In a subgroup of patients with HCT-CI score
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Matza LS, Deger KA, Howell TA, Koetter K, Yeager AM, Hogge D, Fisher V, Louie AC, Chung KC Abstract Aims Acute myeloid leukemia (AML) treatment typically involves remission induction chemotherapy followed by consolidation chemotherapy. New treatments for AML have recently been introduced, including a chemotherapy formulation called CPX-351, which is administered via less time-intensive IV infusion than the standard "7 + 3" continuous infusion regimen of cytarabine plus an anthracycline. The purpose of this study was to estimate utilities that could be used in economic modeling of AM...
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
Survival rate of patients with chemorefractory acute myeloid leukemia (AML) or myelodysplastic syndrome with excess blasts (MDS-EB) is poor. Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy in these patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This report presents a full-mouth implant-retained reconstruction in a 35-year-old male patient who had undergone alloHCT for treatment of acute myeloid leukemia and developed sclerotic cGVHD afterwards. Implant-retained prosthetics might be a practicable treatment for patients with these complications.
Source: Quintessence International - Category: Dentistry Source Type: research
Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. This first-in-human phase 1/2 study evaluated enasidenib doses of 50 to 650 mg/d, administered in continuous 28-day cycles, in patients with mutant-IDH2 hematologic malignancies. Overall, 214 of 345 patients (62%) with relapsed or r...
Source: Blood - Category: Hematology Authors: Tags: Myeloid Neoplasia, Clinical Trials and Observations Source Type: research
ppe Rossi Considerable progress has been made in the treatment of acute myeloid leukemia (AML). However, current therapeutic results are still unsatisfactory in untreated high-risk patients and poorer in those with primary refractory or relapsed disease. In older patients, reluctance by clinicians to treat unfit patients, higher AML cell resistance related to more frequent adverse karyotype and/or precedent myelodysplastic syndrome, and preferential involvement of chemorefractory early hemopoietic precursors in the pathogenesis of the disease further account for poor prognosis, with median survival lower than six month...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Pre-engraftment syndrome (PES) is as a unique clinical manifestation with non-infectious fever and erythematous skin rash before neutrophil engraftment following cord blood transplantation (CBT) [1-11]. Although the incidence and severity of graft-versus-host disease (GVHD) after single CBT is usually lower compared with conventional adult donor hematopoietic cell transplantation (HCT) [12-15], the incidence of PES after CBT has been reported to be high, ranging from 20 to 78% [1-7].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Opinion statementAcute myeloid leukemia (AML) patients with a complex karyotype (CK-AML) show at least 3 unrelated clonal cytogenetic abnormalities with notoriously poor outcome. Such cases fall into either AML with myelodysplasia-related changes or therapy-related AML in the current World Health Organization classification of AML. Allogeneic stem cell transplantation is one of the only treatment modalities that can provide a long-term survival benefit and is recommended as a consolidative treatment in patients who are able to achieve complete remission. Unfortunately, transplantation is also associated with a higher relap...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia | Study | Transplants